Available Technologies

Browse Penn-owned technologies available for licensing.

HOME SEARCH RSS FEED

Search Results - immunology

12 Results Sort By:

Adoptive T cell therapy for cancer using Mutant KRAS-specific T cell receptors for T cell engineering

We have isolated, cloned, and characterized multiple T cell receptors (TCRs) from human donors specific for common mutations in KRAS and restricted to highly prevalent HLA types. These TCRs, protected by a Penn provisional filing, are suitable for T cell engineering for the adoptive immunotherapy of cancer patients of select HLA types and tumors expressing...

Published: 7/8/2021

Inventor(s):

Keywords(s):

Category(s):

Gum-health promoting smart dental implant system

Dental implant that inhibits plaque accumulation and gingival tissue inflammation by photobiomodulation therapy delivered by embedded light-emitting diodes (LEDs) powered by electricity generated from the patient’s own oral motion. Problem: More than half of adults will lose one or more teeth in their lifetime. When a patient loses a tooth the...

Published: 2/9/2021

Inventor(s):

Keywords(s):

Category(s):

Rapid pathogen diagnostic through amplification of red blood cell-associated DNA

Problem: Sepsis, an overwhelming and life-threatening response to infection, is the most common cause of death in US hospitals. Sepsis is associated with a mortality rate of 25–30% and mortality due to septic shock is 50–85%. Rapid diagnosis and intervention in sepsis are essential given an increased mortality rate of 8% for every hour...

Published: 11/24/2020

Inventor(s):

Keywords(s):

Category(s):

Rapid and ultrasensitive SARS-CoV-2 antigen detection for acute COVID-19 screening in community settings

rss.brief>A portable point-of-care device for rapid and sensitive detection of acute SARS-CoV-2 infections. Problem: The COVID-19 pandemic has infected over 40 million people worldwide as of mid-October 2020, causing more than 1 million deaths. Up to 50-80% of transmissions occur from asymptomatic patients. Current tests can have a turnaround time...

Published: 11/11/2020

Inventor(s):

Keywords(s):

Category(s):

Antibodies for targeting CAR-T cells to acute Myeloid Leukemia cells

Technology Overview: Acute myeloid leukemia (AML) is a major form of acute leukemia in elder adults. The treatment of AML has changed little in the past decades and the overall 5-year survival rate remains very poor in the AML patients. AML relapsed from chemotherapy is highly aggressive with poor prognosis. While adaptive cell therapy via chimeric...

Published: 11/5/2020

Inventor(s):

Keywords(s):

Category(s):

Antibody discovery platform for CAR-T cell targeting and drug conjugation

Technology Overview: Screening platform for identification of potent and specific nanobodies for (i) directing CAR-T cells to cancer cells, (ii) drug conjugation, or (iii) tumor imaging or diagnosis. Identification of antibodies capable of mediating CAR-T killing is challenging due to several reasons. First, the antibody has to have certain affinity...

Published: 11/2/2020

Inventor(s):

Keywords(s):

Category(s):

Lipid nanoparticle-based mRNA delivery for CAR T-cell engineering

A library of ionizable lipid nanoparticles (LNPs) was screened for ability to deliver mRNA to T-cells, leading to an optimized LNP formulation for delivery of mRNA to T-cells. This thereby enhances the ability to generate transient chimeric antigen receptor (CAR)-expressing T-cells for cancer immunotherapy. Problem: Chimeric antigen receptor (CAR)...

Published: 5/4/2020

Inventor(s):

Keywords(s):

Category(s):

Therapeutic targets for T-cell lymphomas and other types of cancer

Interdependence of oncogenic and epigenetic mechanisms in T-cell lymphoma. Technology Overview: Anaplastic large cell lymphoma (ALCL) is a highly malignant type of Non-Hodgkin’s T cell lymphoma in which chromosomal translocation leads to the expression of a fusion oncoprotein Tyrosine Kinase - Nucleophosmin/Anaplastic Lymphoma Kinase or NPM/ALK. Dr....

Published: 3/20/2020

Inventor(s):

Keywords(s):

Category(s):

Antibodies for targeting CAR-T cells to neuroendocrine tumors

Technology Overview: Neuroendocrine tumors (NETs) pose serious threats to patients’ well-being as malignant diseases, and most patients with metastatic NETs succumb to the disease. Using Sequential Tumor-related Antibody and antigen Retrieving (STAR) technology Dr. Xianxin Hua, MD, PhD at the University of Pennsylvania Medical School and his...

Published: 3/20/2020

Inventor(s):

Keywords(s):

Category(s):

Fully human anti-mesothelin CAR with low immunogenicity for in vivo persistence of anti-tumor engineered T cells

The fully human CAR targets mesothelin, a surface protein overexpressed in several cancer types. P4, a human antibody fragment that binds human mesothelin with high specificity, is fused to T cell signaling domains such as 28z. The T cells engineered to express this CAR are shown to shrink tumors in a mouse model bearing human ovarian tumors overexpressing...

Published: 1/29/2020

Inventor(s):

Keywords(s):

Category(s):

1 2